Institut Pasteur Massive On-line Open Courses - Clinical trials in infectious and tropical diseases
We are broadcasting Massive On-line Open Courses (MOOCs) related to infectious diseases on a public and free on-line Platform (MOOCS are available in English and French). We publish around 8-10 MOOCs per year on different issues which shall be of particular interest to learners in Africa. All MOOCs are open for free, but it is also possible to take an on-line exam to obtain a certificate, with fees. Learners who obtain a certificate to 5 MOOCs are awarded with the On-line Diploma of Infectious Diseases of Institut Pasteur.
Currently, our MOOC on Clinical trials in infectious and tropical diseases is open.
https://www.fun-mooc.fr/courses/course-v1:pasteur+96018+session01/about
And our MOOC on Malaria will start on October 19th. Registrations are already open.
https://www.fun-mooc.fr/courses/course-v1:pasteur+96010+session02/about
12th EDCTP forum
Only one month left to submit your abstract and scientific symposia applications for the upcoming 12th hashtagEDCTP Forum !
- Deadline: 23 February
Submit your hashtagabstract here: https://lnkd.in/dNqSieFx
Submit your hashtagsymposia here: https://lnkd.in/dKdYn4CB
The forum will take place in Kigali (Rwanda) from the 15-20 June 2025.
HIV & ADOLESCENCE - November 2020
The International Workshop on HIV & Adolescence 2020 is taking place as a series of virtual sessions during the month of November with the aim to share experiences, knowledge and best practices on optimizing the care of adolescents living with HIV across the spectrum of health and developmental needs.
Each week during the HIV and Adolescence Month, the Children and AIDS Learning Collaborative will provide highlights from the workshop in partnership between UNICEF and Virology Education. This week featured a session on engagement of young people to inspire change.
We are available to answer any questions or concerns that you may have about your participation. For more information, please contact Rikke Rode at Rikke.Rode@vironet.com
https://www.virology-education.com/event/upcoming/hiv-adolescence/
CEPI: Getting more COVID-19 vaccine for the world
Another CEPI partner, Clover Biopharmaceuticals, has become the latest vaccine developer to sign an advance purchase agreement with COVAX to make their COVID-19 vaccine available to populations worldwide.
Under the new agreement between Clover and our COVAX partner, Gavi, up to 414 million doses are set to be made available to participating countries in 2021 and 2022. CEPI’s significant early investments have been critical to the development of Clover’s vaccine candidate, and were directly linked to access commitments which enabled this deal.
Since late Spring, 2020, CEPI has provided up to $328 million to support preclinical and clinical testing of the candidate vaccine, in addition to scaling-up the biotech’s in-house manufacturing capacity. Clover yesterday announced that its pivotal global Phase 2/3 clinical trial—funded by CEPI—is now fully enrolled, and that interim efficacy data is expected in Q3.
COVAX has now distributed over 100 million vaccines since its launch in February this year. Supply of Clover’s vaccine is anticipated to start in the last quarter of the year, pending Emergency Use Licensure from the World Health Organization (WHO).
To learn more visit https://cepi.net/news_cepi/from-lab-to-potential-jab-clovers-covid-19-vaccine-story/